Matthias E.
- Country
- Germany
- Department
- Klinik und Poliklinik für Nuklearmedizin
Research Overview
- Evaluation of Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Advanced Unresectable or Metastatic NSCLC, BC, PDAC, and CRC.
- Phase Ib Dose-Escalation Study of [177Lu]Lu-NeoB with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and as Monotherapy in Recurrent Glioblastoma
- A Randomized Controlled Trial Evaluating the Efficacy of Lutetium (177Lu) Vipivotide Tetraxetan in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving Androgen Deprivation Therapy
Data & Insights
Has run more than one trial at 79 of 146 partner sites.
Specializations
Prostate Cancer Research
The investigator specializes in treating various stages of prostate cancer, with particular emphasis on metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive conditions. Their work encompasses both diagnostic and therapeutic approaches using radioligand therapy.
- Advanced Prostate Cancer Treatment
- PSMA-Targeted Therapies
- Neuroendocrine Prostate Cancer
Breast Cancer Studies
Focus areas include advanced breast cancer treatment, particularly in estrogen receptor-positive and HER2-negative cases. The investigator explores innovative therapeutic combinations including radioligand treatments with conventional therapies.
- Metastatic Breast Cancer
- Hormone Receptor-Positive Disease
- Combined Therapy Approaches
Additional Oncological Focus
The investigator's expertise extends to various other cancer types, including CNS lymphoma, glioblastoma, and multiple solid tumors. Their research includes work with advanced imaging techniques and novel therapeutic approaches.
- Neurological Cancers
- Pancreatic Cancer
- Colorectal Cancer
- Lung Cancer
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.